Are you curious about pertuzumab and how it works in the medical field? Do you want to learn everything there is to know about this powerful medication, including its indications, dosing, and side effects? Look no further! In this comprehensive guide, we will break down all the information you need to understand pertuzumab. From breast cancer treatment to its unique mechanism of action, we've got you covered.
Pertuzumab (brand name Perjeta) is a prescription medication used to treat breast cancer. It’s a type of targeted therapy that works by interfering with the growth and spread of cancer cells. Pertuzumab is given as an infusion into a vein (IV). It’s usually given with other cancer medications.
Common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, tiredness, low blood cell counts, and infusion-related reactions. Serious side effects can also occur. Pertuzumab can interact with other medications, herbs, or vitamins you might be taking.
Pertuzumab is a monoclonal antibody that targets the HER2 protein. The HER2 protein is found on the surface of some breast cancer cells. About 1 out of every 5 breast cancers is HER2-positive. These types of breast cancers tend to grow and spread more quickly than other types of breast cancer. Pertuzumab slows or stops the growth of HER2-positive breast cancer cells by binding to the HER2 protein and preventing it from working properly
Pertuzumab is a humanized monoclonal antibody that targets the HER2 protein. It is used in combination with other cancer treatments, such as trastuzumab and docetaxel, to treat HER2-positive breast cancer.
Pertuzumab can cause serious side effects, including heart problems, gastrointestinal problems, and infusion reactions.
Some common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, fatigue, muscle pain, joint pain, and skin rash. These side effects usually go away after a few weeks of treatment.
Pertuzumab is a monoclonal antibody that works by targeting a protein called HER2, which is found on the surface of some cancer cells. By targeting this protein, pertuzumab can help to kill cancer cells or stop them from growing.
Like all medications, pertuzumab can cause side effects. The most common side effects of pertuzumab include:
• Nausea and vomiting
• Diarrhea
• Skin rash or itching
• Fatigue
• Headache
• Musculoskeletal pain
Less common side effects of pertuzumab include:
• Low blood counts (anemia, neutropenia, thrombocytopenia)
• Infusion-related reactions (fever, chills, nausea/vomiting, low blood pressure)
• Heart problems (heart failure, left ventricular ejection fraction [LVEF] decrease)
As a comprehensive guide to understanding pertuzumab, this article has discussed the drug's indications, dosing, and potential side effects. In summary, pertuzumab is indicated for use in the treatment of non-small cell lung cancer and HER2-positive breast cancer. It is given as an intravenous infusion every three weeks with or without other treatments depending on each patient’s individual case. The most common side effects associated with its use include fatigue, nausea ,and diarrhea.
1.
Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.
2.
Chronic pain and poor sleep are troublesome bed partners.
3.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
4.
Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?
5.
combating racial discrimination in next-generation breast cancer screening.
1.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
2.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
3.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
3.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation